The username/email didn't match the password, please try again!

The email you have inserted is not registered at Medicon Valley Online. If you wish to gain access to a specific organization profile please speak to one of the registered contacts of that organization. The registered contacts can usually be found on the profile page of that organization.

The email you have inserted is not in our database. Plese try again!

To add a compound to a pipeline your organisation needs to be registered as a biotech or pharmaceutical company at Medicon Valley Online. If your organisation is already registered please click on the Sign in button below. If you wish to register a new organisation, please click the Register button.

To add a service your organisation needs to be registered at Medicon Valley Online as a member of Medicon Valley Alliance and have paid the one time fee of 2300 EUR for the service section. If this has been accomplished please, just click the Sign in button below. If you want access to the services section or media about it please send your contact details to contact@mediconvalleyonline.com and we will get back to you.

Please enter your email address in the field below. Once submitted a message, with an authorization link, will be sent to this address so that you can set a new password for your account. You will have access to you account again in a couple of minutes. Thank you for your patience.

Email Print PDF Bookmark | | More

View all organisations

WntResearch

Biotech Company / Biological Products

Member of Medicon Valley Alliance

Description

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies for the treatment of cancer patients meets a large unmet medical need. The company has two projects Foxy-5 and Box-5. The lead project is Foxy-5 which is currently being tested in vivo models and is planned to enter and finalize phase 1 clinical trials in metastatic cancer in 2012. Foxy-5 was well tolerated in two toxicology studies, both in rat and dog, finished in summer 2011. Cancer is a worldwide problem that affects millions of people. Epithelial cancers like breast and colorectal cancer contributes with approximately 20% of all cancer cases in USA and only in 2009, 290 000 new cases were found, which results in at least three times that figure of cancer cases worldwide, globally, 1 070 000 persons die of breast and colorectal cancer each year. Professor Tommy Andersson and his research group have reported a correlation between low/no level of Wnt5a, in the epithelial cancers breast, colorectal and prostate, and high risk of metastasis induction leading to decreasing chances of surviving the cancer for these patients. WntResearch has patent the formylated hexapeptide, Foxy-5, taken from the Wnt5a sequence, that mimics the ability of Wnt5a to impair migration of epithelial cancer cells and acting anti-metastatic in a breast cancer POC study in mice.

Jobs Top

Recruitment Options

To increase your recruitment options, Medicon Valley Online collaborates with the world's largest career network, Monster Worldwide. This gives all MVA members a better distribution and pricing of job advertisements, a free trial access to approximately 100 million CV's based in over 50 countries, and free advisory and personal contact with Monster Key Account Managers in the region.

Read about how you can benefit from this partnership.